(Reuters) - NPS Pharmaceuticals Inc said marketing application for its hormone therapy will be delayed as U.S. health regulators directed the company to change instructions for using the device to deliver the drug. The biopharmaceutical company now expects to file the marketing application of the experimental hypoparathyroidism treatment in mid-2013. NPS Pharma had earlier expected to file for marketing by the end of this year. Hypoparathyroidism is a condition where the parathyroid glands do not produce enough hormone, causing low levels of calcium in the blood. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment